GRTX - Galera Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

234.7M

Cash

47.75M

Avg Qtr Burn

-10.93M

Short % of Float

1.92%

Insider Ownership

3.46%

Institutional Own.

31.63%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Avasopasem Manganese (GC4419) Details Head and neck cancer, Cancer Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rucosopasem Details Pancreatic cancer, Cancer	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rucosopasem Details Cancer, Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avasopasem Manganese (GC4419) Details Lung cancer, Esophagitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avasopasem Manganese (GC4419) Details Infectious disease, COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.